NYSE:BDX - Becton, Dickinson and Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $280.29
  • Forecasted Upside: 22.67 %
  • Number of Analysts: 15
  • Breakdown:
  • 0 Sell Ratings
  • 7 Hold Ratings
  • 7 Buy Ratings
  • 1 Strong Buy Ratings
$228.48
▼ -3.39 (-1.46%)
1 month | 3 months | 12 months
Get New Becton, Dickinson and Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BDX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$280.29
▲ +22.67% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for Becton, Dickinson and in the last 3 months. The average price target is $280.29, with a high forecast of $300.00 and a low forecast of $260.00. The average price target represents a 22.67% upside from the last price of $228.48.
Buy
The current consensus among 15 polled investment analysts is to buy stock in Becton, Dickinson and. This rating has held steady since April 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 0 sell ratings
6/2/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
8/31/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
11/29/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 0 sell ratings
2/27/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 7 hold ratings
  • 0 sell ratings
5/27/2020
  • 1 strong buy ratings
  • 7 buy ratings
  • 7 hold ratings
  • 0 sell ratings
8/25/2020
  • 1 strong buy ratings
  • 7 buy ratings
  • 7 hold ratings
  • 0 sell ratings
10/24/2020
  • 1 strong buy ratings
  • 7 buy ratings
  • 7 hold ratings
  • 0 sell ratings
11/23/2020

Latest Recommendations

  • 1 strong buy ratings
  • 7 buy ratings
  • 7 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/6/2020Morgan StanleyLower Price TargetEqual Weight$270.00 ➝ $262.00Low
i
10/12/2020Raymond JamesLower Price TargetOutperform$285.00 ➝ $270.00Low
i
10/2/2020The Goldman Sachs GroupUpgradeBuy ➝ Conviction-BuyMedium
i
Rating by Amit Hazan at The Goldman Sachs Group, Inc.
8/27/2020Morgan StanleyLower Price TargetEqual Weight$285.00 ➝ $270.00High
i
8/10/2020UBS GroupBoost Price TargetNeutral$265.00 ➝ $280.00Low
i
8/10/2020Morgan StanleyBoost Price TargetEqual Weight$248.00 ➝ $285.00Low
i
8/7/2020Raymond JamesBoost Price TargetOutperform$265.00 ➝ $285.00Medium
i
7/15/2020SVB LeerinkBoost Price TargetMarket Perform$262.00 ➝ $277.00Medium
i
Rating by Richard Newitter at SVB Leerink LLC
7/9/2020BarclaysUpgradeEqual Weight ➝ Overweight$300.00Medium
i
7/2/2020William BlairReiterated RatingOutperformLow
i
Rating by B. Weinstein at William Blair
6/25/2020Morgan StanleyLower Price TargetEqual Weight$255.00 ➝ $248.00High
i
6/25/2020Raymond JamesLower Price TargetPositive ➝ Outperform$290.00 ➝ $265.00High
i
5/31/2020The Goldman Sachs GroupInitiated CoverageBuy$278.00Low
i
5/14/2020Piper SandlerBoost Price TargetOverweight$286.00 ➝ $296.00Low
i
5/12/2020KeyCorpReiterated RatingHoldLow
i
Rating by Matthew Mishan at KeyCorp
5/8/2020SVB LeerinkReiterated RatingMarket Perform$245.00 ➝ $262.00Low
i
5/8/2020CfraLower Price TargetHold$285.00 ➝ $278.00Medium
i
5/8/2020UBS GroupBoost Price TargetNeutral$260.00 ➝ $265.00Medium
i
5/8/2020Stifel NicolausBoost Price TargetBuy$265.00 ➝ $280.00Medium
i
5/8/2020Raymond JamesBoost Price TargetOutperform$283.00 ➝ $290.00Low
i
5/8/2020CitigroupBoost Price TargetNeutral$234.00 ➝ $260.00Low
i
5/8/2020Wells Fargo & CompanyReiterated RatingBuyLow
i
4/14/2020BarclaysReiterated RatingHold$266.00Low
i
4/8/2020SVB LeerinkLower Price TargetMarket Perform$269.00 ➝ $245.00High
i
4/8/2020Wells Fargo & CompanyLower Price TargetOverweight$279.00 ➝ $270.00High
i
4/1/2020Stifel NicolausLower Price TargetBuy$280.00 ➝ $265.00Medium
i
3/27/2020CitigroupLower Price TargetNeutral$260.00 ➝ $234.00Medium
i
3/27/2020Morgan StanleyLower Price TargetEqual Weight$271.00 ➝ $255.00Medium
i
3/4/2020CitigroupInitiated CoverageNeutral$260.00Medium
i
2/7/2020Morgan StanleyLower Price TargetHold ➝ Equal Weight$287.00 ➝ $271.00Medium
i
2/7/2020Wells Fargo & CompanyLower Price TargetOverweight$285.00 ➝ $279.00Medium
i
Rating by Larry Biegelsen at Wells Fargo & Company
2/7/2020Raymond JamesDowngradeStrong-Buy ➝ Outperform$288.00 ➝ $283.00Medium
i
2/6/2020CowenDowngradeOutperform ➝ Market Perform$306.00 ➝ $275.00High
i
Rating by Josh Jennings at Cowen Inc
2/6/2020Piper SandlerBoost Price TargetOverweight$279.00 ➝ $285.00High
i
2/6/2020CfraDowngradeBuy ➝ Hold$304.00 ➝ $285.00High
i
2/3/2020CowenReiterated RatingOutperform ➝ Outperform$255.00 ➝ $305.00High
i
1/22/2020KeyCorpBoost Price TargetOverweight$284.00 ➝ $298.00Low
i
1/8/2020BarclaysDowngradeOverweight ➝ Equal Weight$275.00Low
i
12/20/2019JPMorgan Chase & Co.Boost Price TargetOverweight$285.00 ➝ $300.00Low
i
12/17/2019Morgan StanleyBoost Price TargetEqual Weight$261.00 ➝ $287.00Low
i
12/16/2019Stifel NicolausBoost Price TargetBuy$275.00 ➝ $295.00Low
i
11/13/2019KeyCorpLower Price TargetOverweight$262.00 ➝ $256.00Medium
i
9/6/2019Wells Fargo & CompanyBoost Price TargetOutperform$270.00 ➝ $290.00N/A
i
9/5/2019Wells Fargo & CompanyReiterated RatingBuyLow
i
Rating by Larry Biegelsen at Wells Fargo & Company
8/6/2019Piper Jaffray CompaniesLower Price TargetOverweight$267.00 ➝ $266.00Medium
i
7/16/2019Morgan StanleyBoost Price TargetEqual Weight$250.00 ➝ $261.00Low
i
6/28/2019Raymond JamesBoost Price TargetStrong-Buy$265.00 ➝ $288.00Low
i
5/13/2019Wells Fargo & CompanyLower Price TargetOutperform$280.00 ➝ $265.00Low
i
5/13/2019BarclaysUpgradeEqual Weight ➝ Overweight$266.00Low
i
5/10/2019BMO Capital MarketsLower Price TargetMarket Perform$272.00 ➝ $270.00Low
i
5/10/2019Morgan StanleyLower Price TargetEqual Weight$255.00 ➝ $250.00High
i
5/10/2019UBS GroupLower Price TargetNeutral$265.00 ➝ $250.00High
i
5/10/2019KeyCorpReiterated RatingPositive ➝ Overweight$273.00 ➝ $262.00High
i
4/15/2019BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$260.00 ➝ $266.00Low
i
Rating by Kristen Stewart at Barclays PLC
3/19/2019Raymond JamesLower Price TargetStrong-Buy ➝ Strong-Buy$290.00 ➝ $280.00Medium
i
2/5/2019Piper Jaffray CompaniesBoost Price TargetOverweight$274.00Low
i
1/2/2019Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$265.00 ➝ $240.00Low
i
1/2/2019CitigroupLower Price TargetBuy ➝ Buy$279.00 ➝ $256.00Low
i
12/6/2018Deutsche Bank AktiengesellschaftInitiated CoverageBuy ➝ Buy$280.00Medium
i
11/27/2018UBS GroupInitiated CoverageNeutral$260.00Medium
i
11/13/2018CitigroupLower Price TargetBuy ➝ Buy$289.00 ➝ $279.00Low
i
11/8/2018KeyCorpBoost Price TargetOverweight ➝ Overweight$264.00 ➝ $273.00Medium
i
11/8/2018BarclaysSet Price TargetHold$260.00Medium
i
Rating by Kristen Stewart at Barclays PLC
11/7/2018Wells Fargo & CompanyLower Price TargetOutperform$290.00 ➝ $280.00High
i
11/6/2018Piper Jaffray CompaniesLower Price TargetOverweight$250.00Medium
i
10/15/2018BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$278.00High
i
10/4/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$250.00 ➝ $280.00High
i
9/6/2018Wells Fargo & CompanyBoost Price TargetOutperform$275.00 ➝ $290.00Low
i
8/8/2018CitigroupBoost Price TargetBuy ➝ Buy$274.00 ➝ $283.00Medium
i
8/3/2018Royal Bank of CanadaReiterated RatingHold$248.00Low
i
8/3/2018KeyCorpReiterated RatingBuy$264.00Low
i
6/21/2018JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$175.00Medium
i
4/10/2018CitigroupUpgradeNeutral ➝ Buy$237.00 ➝ $251.00Low
i
3/5/2018BMO Capital MarketsInitiated CoverageMarket Perform$249.00Low
i
2/7/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$245.00 ➝ $250.00Low
i
2/6/2018Piper Jaffray CompaniesReiterated RatingOverweight$223.00 ➝ $260.00Low
i
1/19/2018Bank of AmericaReiterated RatingBuy ➝ Buy$260.00Medium
i
1/5/2018CitigroupUpgradeSell ➝ NeutralLow
i
1/5/2018KeyCorpInitiated CoverageOverweight ➝ Overweight$260.00Low
i
1/3/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$245.00Medium
i
12/29/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy ➝ Buy$239.00 ➝ $260.00Low
i
Rating by Kristen Stewart at Deutsche Bank Aktiengesellschaft
12/14/2017ArgusBoost Price TargetAverage ➝ Buy$235.00Low
i
11/3/2017Stifel NicolausReiterated RatingBuy$245.00N/A
i
11/3/2017Morgan StanleyBoost Price TargetEqual Weight$205.00 ➝ $245.00N/A
i
11/3/2017Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$210.00 ➝ $230.00N/A
i
10/25/2017Royal Bank of CanadaReiterated RatingHold$210.00N/A
i
10/24/2017Wells Fargo & CompanyReiterated RatingOutperform ➝ Positive$225.00 ➝ $235.00N/A
i
9/22/2017Wells Fargo & CompanyInitiated CoverageOutperform ➝ Outperform$225.00Low
i
9/12/2017Piper Jaffray CompaniesReiterated RatingBuy$213.00High
i
8/14/2017CowenReiterated RatingBuy$230.00Low
i
8/10/2017BarclaysReiterated RatingEqual Weight$205.00 ➝ $210.00Low
i
8/9/2017Stifel NicolausReiterated RatingBuyLow
i
7/21/2017Bank of AmericaReiterated RatingBuy$200.00 ➝ $225.00Medium
i
7/10/2017CowenReiterated RatingOutperform$200.00 ➝ $230.00Low
i
6/30/2017Raymond JamesUpgradeOutperform ➝ Strong-Buy$210.00 ➝ $180.00Low
i
4/24/2017Evercore ISIUpgradeIn-Line ➝ Outperform$186.00 ➝ $200.00High
i
4/13/2017Royal Bank of CanadaReiterated RatingHold$177.00Low
i
3/29/2017Jefferies Financial GroupReiterated RatingBuy$200.00Low
i
1/6/2017Royal Bank of CanadaReiterated RatingHold$177.00N/A
i
1/5/2017Raymond JamesReiterated RatingStrong-Buy ➝ Outperform$200.00 ➝ $180.00N/A
i
1/5/2017UBS GroupDowngradeStrong-Buy ➝ OutperformN/A
i
1/3/2017JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$190.00 ➝ $175.00N/A
i
11/21/2016SVB LeerinkReiterated RatingMarket Perform$180.00 ➝ $185.00N/A
i
11/18/2016UBS GroupReiterated RatingBuy$195.00N/A
i
11/4/2016Deutsche Bank AktiengesellschaftReiterated RatingBuy$197.00 ➝ $189.00N/A
i
10/21/2016ArgusReiterated RatingBuy$185.00N/A
i
Rating by David Toung at Argus
9/23/2016CitigroupDowngradeNeutral ➝ Sell$167.00 ➝ $165.00N/A
i
8/16/2016CowenReiterated RatingOutperform$185.00N/A
i
8/9/2016SVB LeerinkReiterated RatingHoldN/A
i
Rating by Richard Newitter at SVB Leerink LLC
8/5/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
8/5/2016UBS GroupBoost Price TargetBuy$182.00 ➝ $195.00N/A
i
7/28/2016Jefferies Financial GroupBoost Price TargetBuy$190.00 ➝ $192.00N/A
i
7/12/2016Bank of AmericaReiterated RatingBuyN/A
i
Rating by Derik De Bruin at Bank of America Co.
6/12/2016ArgusReiterated RatingBuyN/A
i
Rating by David Toung at Argus
6/1/2016Evercore ISIDowngradeBuy ➝ HoldN/A
i
5/18/2016SVB LeerinkReiterated RatingHold$175.00N/A
i
Rating by Richard Newitter at SVB Leerink LLC
5/12/2016Bank of AmericaReiterated RatingBuyN/A
i
Rating by Derik De Bruin at Bank of America Co.
5/9/2016Royal Bank of CanadaBoost Price TargetSector Perform$153.00 ➝ $169.00N/A
i
5/8/2016SVB LeerinkReiterated RatingHoldN/A
i
Rating by Richard Newitter at SVB Leerink LLC
5/8/2016Morgan StanleyReiterated RatingHoldN/A
i
Rating by David Lewis at Morgan Stanley
5/7/2016Evercore ISIReiterated RatingHold$154.00 ➝ $165.00N/A
i
5/3/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
Rating by Michael Weinstein at JPMorgan Chase & Co.
4/8/2016The Goldman Sachs GroupBoost Price Target$156.00 ➝ $157.00N/A
i
3/16/2016Jefferies Financial GroupReiterated RatingBuy$175.00N/A
i
3/10/2016Jefferies Financial GroupReiterated RatingBuy$175.00N/A
i
2/11/2016Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$155.00 ➝ $163.00N/A
i
2/4/2016SVB LeerinkLower Price TargetMarket Perform$157.00N/A
i
2/4/2016The Goldman Sachs GroupLower Price TargetNeutral$155.00 ➝ $152.00N/A
i
2/4/2016CitigroupLower Price TargetNeutral$153.00 ➝ $146.00N/A
i
Rating by Amit Hazan at Citigroup Inc.
2/4/2016Royal Bank of CanadaLower Price TargetSector Perform$162.00 ➝ $153.00N/A
i
1/7/2016CowenBoost Price Target$180.00N/A
i
1/7/2016ArgusReiterated RatingBuy$167.00N/A
i
1/6/2016Evercore ISIDowngradeBuy ➝ Hold$160.00N/A
i
1/4/2016Morgan StanleyDowngradeOverweight ➝ Equal Weight$170.00N/A
i
12/11/2015Raymond JamesBoost Price TargetStrong-Buy$172.00 ➝ $176.00N/A
i
(Data available from 11/24/2015 forward)
Becton, Dickinson and logo
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. It has a strategic partnership with the Biomedical Advanced Research and Development Authority to develop new manufacturing lines for injection devices. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Read More

Today's Range

Now: $228.48
$227.69
$233.41

50 Day Range

MA: $237.16
$231.13
$244.24

52 Week Range

Now: $228.48
$197.75
$286.72

Volume

1,495,374 shs

Average Volume

1,866,849 shs

Market Capitalization

$66.23 billion

P/E Ratio

83.69

Dividend Yield

1.36%

Beta

0.83